Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma
Abstract Renal cell carcinoma (RCC) has emerged as a metabolic disease characterized by dysregulated expression of metabolic enzymes. Patients with metastatic RCC have an unusually poor prognosis and near-universal resistance …